checkAd

Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue At-Home OTC COVID-19 Tests

Nachrichtenquelle: Business Wire (engl.)
06.05.2021, 02:30  |  162   |   |   

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today a retail collaboration with Walgreens to make Quidel’s non-prescription QuickVue At-Home OTC COVID-19 Test available to consumers at 7,600 Walgreens locations across the United States and Puerto Rico. The shelf-stable packages, each containing two of the self-administered rapid antigen tests, can also be ordered online at Walgreens.com for store pick-up or same day delivery.

“This retail collaboration with Walgreens will expedite in-store availability and over-the-counter sales of our QuickVue At-Home OTC COVID-19 antigen tests to consumers nationwide,” said Douglas Bryant, president and CEO of Quidel Corporation. “The ability to pick up the QuickVue At-Home tests at a trusted pharmacy like Walgreens and screen for COVID-19 in the privacy of their homes will give greater peace of mind to countless American families and give added confidence to schools and businesses seeking to fully reopen.”

The QuickVue At-Home OTC COVID-19 Test allows consumers to easily perform the test themselves without a doctor’s prescription and get results in 10 minutes from nasal swab samples. The QuickVue At-Home COVID-19 Test shows excellent performance, with positive results agreeing with PCR 83.5% of the time, and negative results agreeing 99.2% of the time, delivering confidence to individuals running the test and helping to prevent asymptomatic virus spread.

The QuickVue At-Home OTC COVID-19 Test is only for use under the Food and Drug Administration’s Emergency Use Authorization. The QuickVue At-Home OTC COVID-19 Test has not been FDA cleared or approved. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Seite 1 von 3


Quidel Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de

Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue At-Home OTC COVID-19 Tests Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today a retail collaboration with Walgreens to make Quidel’s …

Nachrichten des Autors

Titel
Titel
Titel
Titel